Table 4 Overall survival in subgroups of patients treated with first-line sunitinib (Cohort 2008–2010 and Cohort 2011–2013)
2008–2010 Cohort: mRCC at the initial diagnosis | 2011–2013 Cohort: mRCC | ||||||
|---|---|---|---|---|---|---|---|
n | Median OS in months (95 % C.I.) | p-value | n | Median OS in months (95 % C.I.) | p-value | ||
All patients | 282 | 9.1 (7.2–11.1) | – | 109 | 10.1 (7.2–13.8) | – | |
Fulfilling SUTENT trial eligibility criteria | No | 110 | 6.5 (4.9–8.9) | 38 | 6.9 (3.4–10.9) | ||
Yes | 172 | 11.9 (8.8–14.6) | 0.0014 | 71 | 12.1 (8.9-NR) | 0.0074 | |
Brain metastases | No | 261 | 9.3 (7.6–11.9) | 101 | 10.9 (7.8–18.0) | ||
Yes | 21 | 4.3 (2.1–11.5) | 0.0820 | 8 | 2.5 (0.8–7.5) | 0.0125 | |
WHO performance status | 0–1 | 248 | 10.3 (8.4–13.0) | 100 | 11.3 (7.8–18.0) | ||
2–4 | 34 | 3.3 (1.8–6.2) | <0.0001 | 9 | 1.4 (0.6–7.5) | <0.0001 | |
Histology | Clear cell | 204 | 10.0 (7.6–13.3) | 81 | 10.6 (7.2–20.3) | ||
Non-clear cell | 78 | 6.9 (5.4–11.0) | 0.0809 | 28 | 10.0 (3.5–13.8) | 0.3325 | |
Age | <65 years | 162 | 8.9 (6.5–10.8) | 64 | 11.3 (7.2–20.3) | ||
> = 65 years | 120 | 10.0 (6.5–13.8) | 0.8373 | 45 | 10.0 (5.3–16.6) | 0.4294 | |
Patients with an intermediate prognosis (or favourable prognosis)a | 145 | 14.6 (11.5–16.0) | – | 65 | 16.6 (10.1-NR) | – | |
Fulfilling SUTENT trial eligibility criteria | No | 43 | 11.9 (6.5–18.3) | 20 | 10.9 (2.7-NR) | ||
Yes | 102 | 14.8 (10.8–16.1) | 0.2897 | 45 | 18.0 (10.1-NR) | 0.1212 | |
Brain metastases | No | 136 | 14.6 (10.7–16.0) | 61 | 16.6 (10.9-NR) | ||
Yes | 9 | 11.9 (4.3–29.3) | 0.8072 | 4 | 6.9 (2.5-NR) | 0.2282 | |
WHO performance status | 0–1 | 143 | 14.4 (10.8–16.0) | 64 | 16.6 (10.1-NR) | ||
2–4 | 2 | – | 0.2304 | 1 | – | 0.2471 | |
Histology | Clear cell | 111 | 14.8 (11.8–16.2) | 49 | 18.0 (10.0-NR) | ||
Non-clear cell | 34 | 11.5 (6.3–17.7) | 0.1954 | 16 | 13.8 (2.7-NR) | 0.3135 | |
Age | <65 years | 87 | 10.8 (7.2–15.7) | 36 | 12.1 (7.2-NR) | ||
> = 65 years | 58 | 16.1 (12.4–18.8) | 0.2606 | 29 | 16.6 (8.5-NR) | 0.7157 | |
Patients with a poor prognosis | 137 | 6.1 (4.9–7.7) | – | 44 | 6.5 (3.4–10.0) | – | |
Fulfilling SUTENT trial eligibility criteria | No | 67 | 4.7 (3.3–6.9) | 18 | 3.5 (1.3–7.8) | ||
Yes | 70 | 6.8 (5.3–10.7) | 0.0145 | 26 | 6.6 (3.8-NR) | 0.0720 | |
Brain metastases | No | 125 | 6.5 (5.3–8.4) | 40 | 6.5 (3.8–10.1) | ||
Yes | 12 | 2.1 (0.7–4.2) | 0.0062 | 4 | 1.2 (0.8-NR) | 0.0134 | |
WHO performance status | 0–1 | 105 | 6.9 (5.3–9.8) | 36 | 6.6 (3.8–10.1) | ||
2–4 | 32 | 3.1 (1.4–5.5) | <0.0001 | 8 | 1.2 (0.6–7.5) | 0.0087 | |
Histology | Clear cell | 93 | 6.1 (4.6–7.8) | 32 | 6.5 (2.7–10.1) | ||
Non-clear cell | 44 | 5.7 (3.7–10.3) | 0.6585 | 12 | 4.1 (2.6-NR) | 0.9982 | |
Age | <65 years | 75 | 6.9 (4.9–9.8) | 28 | 7.8 (3.8–13.7) | ||
> = 65 years | 62 | 5.4 (3.8–6.8) | 0.4044 | 16 | 3.2 (1.1–6.6) | 0.0256 | |